Mesoblast Ltd ADR MESO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MESO is a good fit for your portfolio.
News
-
FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
-
Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
-
Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
-
Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week
-
Mesoblast Corporate Presentation at Investor Conference
-
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
-
Mesoblast Shares Jump After FDA Nod for Submission of Remestemcel-L Application
-
Mesoblast Gets FDA's Special Pediatric Designation for Revascor Heart Treatment
Trading Information
- Previous Close Price
- $7.42
- Day Range
- $7.30–7.59
- 52-Week Range
- $1.61–8.66
- Bid/Ask
- $7.41 / $7.44
- Market Cap
- $844.52 Mil
- Volume/Avg
- 89,252 / 210,480
Key Statistics
- Price/Earnings (Normalized)
- 0.14
- Price/Sales
- 83.11
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 83
- Website
- https://www.mesoblast.com
Comparables
Valuation
Metric
|
MESO
|
ATXS
|
MORF
|
---|---|---|---|
Price/Earnings (Normalized) | 0.14 | — | — |
Price/Book Value | 1.48 | 2.40 | 4.58 |
Price/Sales | 83.11 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
MESO
ATXS
MORF
Financial Strength
Metric
|
MESO
|
ATXS
|
MORF
|
---|---|---|---|
Quick Ratio | 2.59 | 33.41 | 23.71 |
Current Ratio | 2.71 | 33.83 | 24.13 |
Interest Coverage | — | — | — |
Quick Ratio
MESO
ATXS
MORF
Profitability
Metric
|
MESO
|
ATXS
|
MORF
|
---|---|---|---|
Return on Assets (Normalized) | — | −23.38% | −20.07% |
Return on Equity (Normalized) | — | −40.10% | −20.72% |
Return on Invested Capital (Normalized) | — | −29.23% | −24.50% |
Return on Assets
MESO
ATXS
MORF
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Pgnkxphjxv | Crjc | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Lcgchrrc | Kmddqlt | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Qfjqcyfm | Xmmfwww | $118.7 Bil | |||
Moderna Inc
MRNA
| Vbmnkqr | Ndwzw | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Bgbgqnp | Sbgmkc | $29.7 Bil | |||
argenx SE ADR
ARGX
| Ynhscxkp | Mjdc | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Jzbnpmysr | Prhy | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Pydzddr | Qzhxv | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Vhvnshrnv | Ywd | $15.0 Bil | |||
Incyte Corp
INCY
| Gpthhpgt | Zdvhmhn | $13.5 Bil |